Randomized Trialhigh evidence

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Nature medicine·July 1, 2024·PMID 38858523

Why it matters

Retatrutide, a triple agonist, shows substantial liver fat reduction in MASLD, exceeding effects seen with other agents. This suggests a potential disease-modifying role, addressing both steatosis and cardiometabolic risk factors.

Infographic summary of Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled